CFDE Data Portal | Search MSH2-OT1

	Label	Description
	MSH2-OT1 Gene (Entity type)	ENSG00000235760 - MSH2 overlapping transcript 1
	GSE125956 SYK knockdown 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115384 CELSR2 knockdown 5 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE225901 dexamethasone 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE157960 2 V 3 PROGESTERONE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE217405 3 V 2 OSIMERTINIB MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE190178 MEK CDK8 inhibition 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135030 3 V 1 FLUDARABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 11 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS

MSH2-OT1

ENSG00000235760 - MSH2 overlapping transcript 1

GSE125956 SYK knockdown 4 v 2 human up

A Gene Set from LINCS

GSE115384 CELSR2 knockdown 5 v 1 human dn

A Gene Set from LINCS

GSE225901 dexamethasone 2 v 3 human dn

A Gene Set from LINCS

GSE157960 2 V 3 PROGESTERONE MOUSE UP

A Gene Set from LINCS

GSE217405 3 V 2 OSIMERTINIB MOUSE DN

A Gene Set from LINCS

GSE190178 MEK CDK8 inhibition 1 v 4 human up

A Gene Set from LINCS

GSE135030 3 V 1 FLUDARABINE HUMAN UP

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 11 v 8 human up

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 7 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.